ArticleWiener klinische Wochenschrift2018
Long-term outcomes after acute hypercapnic COPD exacerbation : First-ever episode of non-invasive ventilation.
Article in Wiener klinische Wochenschrift, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 17 citations in OpenAlex.
- Trial
- Development and external validation of an admission-based model for in-hospital mortality in acute exacerbation of COPD: incremental prognostic value of type 2 diabetes mellitus.Frontiers in endocrinology · 2026Observational
- Long-term cohort study of patients presenting with hypercapnic respiratory failure.BMJ open respiratory research · 2024Article
- Hypercapnic Failure in Acute Exacerbated COPD Patients: Severe Airflow Limitation as an Early Warning Signal.Journal of clinical medicine · 2022Article
- Chronic moderate hypercapnia suppresses ventilatory responses to acute CO<sub>2</sub> challenges.Journal of applied physiology (Bethesda, Md. : 1985) · 2022Article
- Mortality and Healthcare Use of Patients with Compensated Hypercapnia.Annals of the American Thoracic Society · 2021Article
- Risk of Readmission and Mortality Following Hospitalization with Hypercapnic Respiratory Failure.Lung · 2020Article
- Elevated COFrontiers in physiology · 2020Article
- How important is oxygen titration in hypercapnic COPD exacerbation?Wiener klinische Wochenschrift · 2019Article
- Oxygen titration in hypercapnic COPD exacerbation.Wiener klinische Wochenschrift · 2019Article
Corrections and comments
- Commented on by
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNon-invasive ventilation (NIV) is used to treat acute hypercapnic respiratory failure (AHRF) in patients with chronic obstructive pulmonary disease (COPD); however, long-term outcomes following discharge are largely unknown. This study aimed to characterize long-term outcomes and identify associated markers in patients with COPD after surviving the first episode of HRF requiring NIV.
methodsThis study retrospectively analyzed 122 patients, mean age 62 ± 8 years, 52% female and forced expiratory volume in 1 s (FEV1) predicted 30 ± 13%, admitted with an acute hypercapnic exacerbation of COPD and receiving a first-ever NIV treatment between 2000 and 2012.
resultsA total of 40% of the patients required hospital readmission due to respiratory reasons within 1 year. Persistent hypercapnia leading to the prescription of domiciliary NIV, older age and lower body mass index (BMI) were risk factors for readmission due to respiratory reasons. Survival rates were 79% and 63% at 1 and 2 years after discharge, respectively. A shorter time to readmission and recurrent hypercapnic failure, lower BMI and acidemia on the first admission, as well as hypercapnia at hospital discharge were correlated with a decreased long-term survival.
conclusionPatients with COPD surviving their first episode of AHRF requiring NIV are at high risk for readmission and death. Severe respiratory acidosis, chronic respiratory failure and a lower BMI imply shorter long-term survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.